Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVALUATE-STEMI: Evolocumab in Anterior STEMI Patients Undergoing Primary PCI
NCT05613426Phase 4Terminated
- Sponsor
- Henan Institute of Cardiovascular Epidemiology
- Start
- Apr 2023
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of evolocumab in ST elevation myocardial infarction (STEMI) (3 arms), sponsored by Henan Institute of Cardiovascular Epidemiology. Primary endpoint: Change in left ventricular ejection fraction at 12 weeks. Started Apr 2023; status: terminated.
02
Drugs
evolocumab
03
Conditions
ST elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT05613426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05613426.